Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | FUCA1 | P04066 | 5/20 | 0.32 |
| ▸ | FUCA2 | Q9BTY2 | 1/20 | 0.31 |
| ▸ | APLNR | P35414 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20046301 | 1.00 | EPHX2 (0.44) | EPHX2CYP2C9TSHRCYP2C19TDP1 | |
| SCHEMBL20541241 | 1.00 | EPHX2 (0.44) | EPHX2CYP2C9TSHRCYP2C19TDP1 | |
| SCHEMBL28021681 | 0.84 | EPHX2 (0.42) | EPHX2 | |
| SCHEMBL24269492 | 0.74 | — | — | |
| SCHEMBL20811096 | 0.74 | — | — | |
| SCHEMBL3488092 | 0.74 | — | — | |
| SCHEMBL25101528 | 0.74 | — | — | |
| SCHEMBL92614 | 0.74 | — | — | |
| SCHEMBL10273860 | 0.74 | — | — | |
| SCHEMBL15533518 | 0.74 | CYP2C9 (0.36) | CYP2C9TSHRCYP2C19TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110785420-B | Oxazepin derivatives as inhibitors of PI 3-kinase activity | 葛兰素史克知识产权开发有限公司 | 2022-04-26 | — | — | CN | disclosed |
| CN-110785420-A | Oxazabenzopyrazole derivatives as inhibitors of PI 3-kinase activity | 葛兰素史克知识产权开发有限公司 | 2020-02-11 | — | — | CN | disclosed |
| US-9884847-B2 | Indazole retinoic acid receptor-related orphan receptor modulators and uses thereof | INNOV17 LLC (US) | 2018-02-06 | — | — | US | disclosed |
| WO-2017184549-A1 | PYRROLOPYRIDINE RETINOIC ACID RECEPTOR-RELATED ORPHAN RECEPTOR MODULATORS AND USES THEREOF | INNOV17 LLC (US) | 2017-10-26 | — | — | WO | disclosed |
| US-20170298060-A1 | PYRROLOPYRIDINE RETINOIC ACID RECEPTOR-RELATED ORPHAN RECEPTOR MODULATORS AND USES THEREOF | INNOV17 LLC | 2017-10-19 | — | — | US | disclosed |
| US-9771374-B2 | Benzimidazole retinoic acid receptor-related orphan receptor modulators and uses thereof | INNOV17 LLC (US) | 2017-09-26 | — | — | US | disclosed |
| US-20170217956-A1 | AZAINDOLE RETINOIC ACID RECEPTOR-RELATED ORPHAN RECEPTOR MODULATORS AND USES THEREOF | INNOV17 LLC (US) | 2017-08-03 | — | — | US | disclosed |
| US-9701663-B2 | Sulfonamide retinoic acid receptor-related orphan receptor modulators and uses thereof | INNOV17 LLC (US) | 2017-07-11 | — | — | US | disclosed |
| US-20170190712-A1 | BENZIMIDAZOLE RETINOIC ACID RECEPTOR-RELATED ORPHAN RECEPTOR MODULATORS AND USES THEREOF | INNOV17 LLC | 2017-07-06 | — | — | US | disclosed |
| US-20170158669-A1 | INDAZOLE RETINOIC ACID RECEPTOR-RELATED ORPHAN RECEPTOR MODULATORS AND USES THEREOF | INNOV17 LLC | 2017-06-08 | — | — | US | disclosed |
| US-20160024057-A1 | INDAZOLE RETINOIC ACID RECEPTOR-RELATED ORPHAN RECEPTOR MODULATORS AND USES THEREOF | INNOV17 LLC (US) | 2016-01-28 | — | — | US | disclosed |
| EP-2069316-B1 | 2,4-DIAMINOQUINAZOLINES FOR SPINAL MUSCULAR ATROPHY | FAMILIES OF SPINAL MUSCULAR ATROPHY (US) | 2015-10-07 | — | — | EP | disclosed |
| WO-2015138276-A2 | RETINOIC ACID RECEPTOR-RELATED ORPHAN RECEPTOR MODULATORS AND USES THEREOF | INNOV17 LLC (US) | 2015-09-17 | — | — | WO | disclosed |
| US-20150252022-A1 | RETINOIC ACID RECEPTOR-RELATED ORPHAN RECEPTOR MODULATORS AND USES THEREOF | INNOV17 LLC | 2015-09-10 | — | — | US | disclosed |
| EP-2615086-A1 | 2,4-Diaminoquinazolines for the treatment of spinal muscular atrophy | Families of Spinal Muscular Atrophy (US) | 2013-07-17 | — | — | EP | disclosed |
| US-7985755-B2 | 2,4-diaminoquinazolines for spinal muscular atrophy | FAMILIES OF SPINAL MUSCULAR ATROPHY (US) | 2011-07-26 | — | — | US | disclosed |
| US-7985755-B2 | 2,4-diaminoquinazolines for spinal muscular atrophy | FAMILIES OF SPINAL MUSCULAR ATROPHY (US) | 2011-07-26 | — | — | US | disclosed |
| US-20090042900-A1 | 2,4-DIAMINOQUINAZOLINES FOR SPINAL MUSCULAR ATROPHY | DECODE CHEMISTRY, INC. (US) | 2009-02-12 | — | — | US | disclosed |
| US-20090042900-A1 | 2,4-DIAMINOQUINAZOLINES FOR SPINAL MUSCULAR ATROPHY | DECODE CHEMISTRY, INC. (US) | 2009-02-12 | — | — | US | disclosed |
| WO-2008016973-A1 | 2,4-DIAMINOQUINAZOLINES FOR SPINAL MUSCULAR ATROPHY | FAMILIES OF SPINAL MUSCULAR ATROPHY (US) | 2008-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170190712-A1 | BENZIMIDAZOLE RETINOIC ACID RECEPTOR-RELATED ORPHAN RECEPTOR MODULATORS AND USES THEREOF | RARB, RARA, RARG | EPHX2 1897/4885CYP2C9 763/4885TSHR 172/4885 |
| US-20170298060-A1 | PYRROLOPYRIDINE RETINOIC ACID RECEPTOR-RELATED ORPHAN RECEPTOR MODULATORS AND USES THEREOF | RARB, RARA, RARG | EPHX2 1523/4885CYP2C9 1323/4885TSHR 171/4885 |
| US-20170158669-A1 | INDAZOLE RETINOIC ACID RECEPTOR-RELATED ORPHAN RECEPTOR MODULATORS AND USES THEREOF | RXRA, RXRB, RARB | EPHX2 1250/4885CYP2C9 386/4885TSHR 176/4885 |
| US-20170217956-A1 | AZAINDOLE RETINOIC ACID RECEPTOR-RELATED ORPHAN RECEPTOR MODULATORS AND USES THEREOF | RARA, RARB, RARG | EPHX2 1659/4885CYP2C9 2130/4885TSHR 126/4885 |
| US-20160024057-A1 | INDAZOLE RETINOIC ACID RECEPTOR-RELATED ORPHAN RECEPTOR MODULATORS AND USES THEREOF | RXRA, RXRB, RARB | EPHX2 1250/4885CYP2C9 386/4885TSHR 176/4885 |
| US-20150252022-A1 | RETINOIC ACID RECEPTOR-RELATED ORPHAN RECEPTOR MODULATORS AND USES THEREOF | RARA, RARB, RARG | EPHX2 905/4885CYP2C9 1545/4885TSHR 109/4885 |
| US-20090042900-A1 | 2,4-DIAMINOQUINAZOLINES FOR SPINAL MUSCULAR ATROPHY | SMN1; SMN2, MUSK, MYT1 | EPHX2 4428/4885CYP2C9 4636/4885TSHR 4604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.